Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis

NCT03290131 is registered in ClinicalTrials.gov with RVL Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03290131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03290131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Lead sponsor
RVL Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2018
Completion date
January 2, 2019
Enrollment
536 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, spasticity, muscle